• Home
  1. Home
  2. Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries
Scientific article
OA Policy
English

Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries

Contributors

Lauper, Kim; Mongin, Denis; Iannone, Florenzo; Klami Kristianslund, Eirik; Kvien, Tore K; Nordström, Dan; Pavelka, Karel; Pombo-Suarez, Manuel; Rotar, Ziga; Santos, Maria Jose; Codreanu, Catalin; Lukina, Galina; Courvoisier, Delphine; Gabay, Cem

Published in

RMD Open, vol. 4, no. 2, e000809

Publication date

2018

Abstract

To compare the real-word effectiveness of subcutaneous tocilizumab (TCZ-SC) and intravenous tocilizumab (TCZ-IV) in rheumatoid arthritis (RA).

Keywords

  • DMARDs
  • Biological therapies
  • Epidemiology
  • Intravenous
  • Rheumatoid arthritis
  • Subcutaneous
  • Tocilizumab

UNIGE affiliation entities

UNIGE research groups

Citation (ISO format)

LAUPER, Kim et al. Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries. In: RMD Open, 2018, vol. 4, n° 2, p. e000809. doi: 10.1136/rmdopen-2018-000809

Main files (1)

Article (Published version)
CC BY-NC

Identifiers

Additional URL for this publication

https://rmdopen.bmj.com/content/4/2/e000809

Journal ISSN

2056-5933
367views
206downloads

Technical informations

Creation

05/12/2019 11:17:00

First validation

05/12/2019 11:17:00

Update

13/10/2025 17:48:46

Status update

03/02/2025 12:56:32

Last indexation

21/08/2026 16:49:05
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated